Followers | 18 |
Posts | 634 |
Boards Moderated | 0 |
Alias Born | 05/19/2017 |
Thursday, February 10, 2022 11:33:23 PM
Novavax Statement on First Administration of its COVID-19 Vaccine in Australia
The first dose of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) was administered today in Australia during a press briefing by The Hon Greg Hunt MP, Federal Minister for Health and Aged Care. Nuvaxovid is the first protein-based COVID-19 vaccine to receive approval for provisional registration by the Therapeutic Goods Administration (TGA).
The TGA granted approval for provisional registration of Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older on January 19.
Novavax is proud to start delivering its vaccine to the people of Australia during a critical time as the pandemic shows no signs of retreat. Australia has played a pivotal role in Novavax' Phase 1 and Phase 2 clinical trials supporting the development of Nuvaxovid. Additionally, a booster trial for Nuvaxovid and a Phase 1/2 trial for a combination seasonal influenza and COVID-19 vaccine are currently underway in Australia.
Novavax and the Commonwealth of Australia have an advance purchase agreement for 51 million doses of Nuvaxovid, with the option for an additional 10 million doses (up to 61 million doses total). Plans are actively underway to begin the delivery process for Nuvaxovid doses across Australia.
Recent NVAX News
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2024 08:10:01 PM
- Novavax to Participate in BofA Securities 2024 Health Care Conference • PR Newswire (US) • 05/13/2024 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 06:39:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:07:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 12:05:26 PM
- Novavax Surges 57% Post $1.4 Billion Sanofi Deal; Apple Boosts Data Centers with AI and Internal Chips, and More News • IH Market News • 05/10/2024 12:02:56 PM
- Novavax Reports First Quarter 2024 Financial Results and Operational Highlights • PR Newswire (US) • 05/10/2024 06:15:00 AM
- Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines • PR Newswire (US) • 05/10/2024 06:00:00 AM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2024 08:53:29 PM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/07/2024 09:21:35 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/07/2024 06:43:55 PM
- Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024 • PR Newswire (US) • 05/07/2024 01:25:00 PM
- Tesla’s April Sales Down 18% in China, Amazon’s Multi-Billion Dollar Cloud Expansion in Singapore, and More News • IH Market News • 05/07/2024 11:44:00 AM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 08:43:09 PM
- Shah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting • GlobeNewswire Inc. • 05/06/2024 10:22:33 AM
- Shah Capital nominates two highly qualified independent director candidates for Novavax • GlobeNewswire Inc. • 04/15/2024 10:00:00 AM
- Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:30:14 AM
- Novavax to Participate in TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/29/2024 09:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:07:50 PM
- Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 02/28/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:30:55 PM
- Goldman Sachs Reconsiders Fed Cuts, LUNR Surges Over 40% in Pre-Market, and More • IH Market News • 02/23/2024 01:03:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:02:36 AM
- Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement • PR Newswire (US) • 02/22/2024 11:00:00 AM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM